Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2.~* Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid tumor~* Patient meets at least 1 of the following criteria:~  * Disease progression despite standard therapies~ * No standard therapies are available or such therapies are not anticipated to result in a durable response~ * Standard therapies are considered unsuitable or have been refused~* Life expectancy \> 12 weeks~* Able to be hospitalized from 1 day prior to the initial dosing until day 15 of the dosing, and from day 27 until day 29 of the dosing~Exclusion Criteria:~* Patient exhibits persistent subjective and objective findings of toxicity ≥ Grade 2 (CTCAE v4.0-JCOG) from the previous cancer treatment with antitumor effect (except of alopecias)~* Received previous treatment with antitumor effect within 21 days prior to the scheduled initial dosing~* Patient had a major surgical procedure within 21 days prior to the scheduled initial dosing or a major surgical procedure scheduled during the course of the study~* Use of an investigational drug or device within 21 days prior to the scheduled initial dosing~* Use of blood transfusion or hematopoietic growth factors within 14 days prior to the scheduled initial dosing~* A positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV)~* Known history of a positive test for human immunodeficiency virus (HIV) infection~* Patient has central nervous system (CNS) or leptomeningeal involvement with clinical symptoms

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASP3026 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).